Lake Street analyst Ben Haynor lowered the firm's price target on P3 Health Partners to $4 from $12.50 and keeps a Buy rating on the shares. The transitional year of 2025 is "finally over, and 2026 looks far brighter," but higher-than-anticipated expenses in Q4 are "likely to leave the company in a situation where the balance sheet becomes an overriding investor concern," the analyst contends. However, despite likely investor balance sheet concerns, the firm sees "the management team making appropriate decisions and fully expect shares to exit this year on an entirely different trajectory once those concerns are resolved," the analyst added.
